Home Cart Sign in  
Chemical Structure| 742112-33-0 Chemical Structure| 742112-33-0

Structure of OSU-03012
CAS No.: 742112-33-0

Chemical Structure| 742112-33-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

OSU-03012 is a potent inhibitor of recombinant PDK-1 with IC50 of 5 μM and 2-fold increase in potency over OSU-02067.

Synonyms: AR-12; PDK1 inhibitor AR-12

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of OSU-03012

CAS No. :742112-33-0
Formula : C26H19F3N4O
M.W : 460.45
SMILES Code : O=C(NC1=CC=C(N2N=C(C(F)(F)F)C=C2C3=CC=C4C5=CC=CC=C5C=CC4=C3)C=C1)CN
Synonyms :
AR-12; PDK1 inhibitor AR-12
MDL No. :MFCD12912272
InChI Key :YULUCECVQOCQFQ-UHFFFAOYSA-N
Pubchem ID :10027278

Safety of OSU-03012

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of OSU-03012

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • PDK1

    PDK-1, IC50:5 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
mouse embryonic stem cells 2.5 or 4 μM 3 days To observe the effect of OSU-03012 on Xist expression and X-chromosome inactivation, results showed that OSU-03012 treatment reduced Xist expression and reversed X-chromosome inactivation. PMC4156765
BMSL2 cells 2.5 μM 3 days To observe the effect of OSU-03012 on Xist expression and X-chromosome inactivation, results showed that OSU-03012 treatment reduced Xist expression and reversed X-chromosome inactivation. PMC4156765
mouse cortical neurons 2.5 μM 4 days To observe the effect of OSU-03012 on Xist expression and X-chromosome inactivation, results showed that OSU-03012 treatment reduced Xist expression and reversed X-chromosome inactivation. PMC4156765
H1155 cells 3 µmol/L 24 hours To evaluate the effect of OSU-03012 in combination with EGFR inhibitors on apoptosis in H1155 cells, the results showed that the combination significantly enhanced apoptosis. PMC3904349
H23 cells 3 µmol/L 24 hours To evaluate the effect of OSU-03012 in combination with EGFR inhibitors on apoptosis in H23 cells, the results showed that the combination significantly enhanced apoptosis. PMC3904349
A549 cells 3 µmol/L 24 hours To evaluate the effect of OSU-03012 in combination with EGFR inhibitors on apoptosis in A549 cells, the results showed that the combination had a weaker effect on apoptosis in A549 cells. PMC3904349
A549 cells ≤12.5 µM 24 hours To evaluate the cytotoxicity of P12-23 and P12-34, results showed no cytotoxicity at concentrations of ≤12.5 µM PMC6246607
A549 cells 1 µM 24 hours To evaluate the inhibitory effect of P12-23 and P12-34 on DENV-2 replication, results showed significant inhibition of viral replication at 1 µM PMC6246607
Primary VS cells 2.1 ± 0.6 μM 48 hours OSU-03012 inhibited cell proliferation with an IC50 of 2.1 ± 0.6 μM PMC2692816
Human malignant schwannoma HMS-97 cells 2.6 ± 0.1 μM 48 hours OSU-03012 inhibited cell proliferation with an IC50 of 2.6 ± 0.1 μM PMC2692816
Normal human Schwann cells > 12 μM 48 hours OSU-03012 had weaker inhibitory effects on normal human Schwann cells with an IC50 > 12 μM PMC2692816
TE1177 cells 5 μM 24 and 48 hours To investigate the effect of OSU-03012 on the cell cycle of TE1177 cells, results showed that OSU-03012 increased the number of cells in the G1 phase. PMC2605165
Ishikawa cells 5μM 48 hours OSU-03012 inhibited the proliferation of Ishikawa cells, induced apoptosis, and caused G2/M cell cycle arrest. PMC8096345
HEC-1A cells 7.5μM 48 hours OSU-03012 inhibited the proliferation of HEC-1A cells, induced apoptosis, and caused G2/M cell cycle arrest. PMC8096345

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
nude mice H1155 tumor xenograft model oral 5 mg/kg single injection To evaluate the effect of OSU-03012 in combination with erlotinib on tumor growth in the H1155 tumor xenograft model, the results showed that the combination significantly suppressed tumor growth. PMC3904349
Stat1−/−mice DENV infection model Intraperitoneal injection 50 mg/kg/day Once daily for 4 weeks To evaluate the protective effect of P12-34 on DENV-infected mice, results showed P12-34 significantly improved survival and reduced viral load PMC6246607
SCID mice Human malignant schwannoma HMS-97 xenograft model Oral 2.5 mg/kg Once daily for 6 days OSU-03012 inhibited the growth of human malignant schwannoma HMS-97 xenografts, reducing tumour volume by 55% PMC2692816
BALB/c-nu mice Ishikawa xenograft model Oral 200 mg/kg/day Once daily for nine weeks OSU-03012 significantly inhibited tumor growth in the Ishikawa xenograft model, reducing tumor volume and weight. PMC8096345

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.17mL

0.43mL

0.22mL

10.86mL

2.17mL

1.09mL

21.72mL

4.34mL

2.17mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Yacoub A, Park MA, et al. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol. 2006 Aug;70(2):589-603.

[2]Zhu J, Huang JW, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004 Jun 15;64(12):4309-18.

[3]Lim MA, Kikani CK, Wick MJ, Dong LQ. Nuclear translocation of 3'-phosphoinositide-dependent protein kinase 1 (PDK-1): a potential regulatory mechanism for PDK-1 function. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14006-11. doi: 10.1073/pnas.2335486100. Epub 2003 Nov 17. PMID: 14623982; PMCID: PMC283536.

[4]Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004 Jun 15;64(12):4309-18. doi: 10.1158/0008-5472.CAN-03-4063. Erratum in: Cancer Res. 2019 Apr 1;79(7):1716. PMID: 15205346.

[5]Gao M, Yeh PY, Lu YS, Hsu CH, Chen KF, Lee WC, Feng WC, Chen CS, Kuo ML, Cheng AL. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma. Cancer Res. 2008 Nov 15;68(22):9348-57. doi: 10.1158/0008-5472.CAN-08-1642. PMID: 19010909.

[6]To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally M, Yapp D, Dunn SE. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor. Mol Pharmacol. 2007 Sep;72(3):641-52. doi: 10.1124/mol.107.036111. Epub 2007 Jun 26. Erratum in: Mol Pharmacol. 2014 Mar;85(3):531-2. PMID: 17595327.

 

Historical Records

Categories